ISRCTN22844568已完成不适用
Randomized phase II/III study of Risedronate in combination with Docetaxel versus Docetaxel alone in patients with hormone refractory prostate cancer
Erasmus Medical Centre (Netherlands)0 个研究点目标入组 480 人开始时间: 2006年1月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Histologically proven prostate adenocarcinoma
- •2. Hormone refractory
- •3. Continued elevated PSA for at least 6 weeks after discontinuation of anti-androgens prior to registration; last PSA level >5 ng/ml
- •4. Stable analgesic regimen for at least one week prior to registration
- •5. Patients without surgical castration must continue on LHRH antagonists
- •6. Adequate bone marrow, liver, renal function
- •7. WHO 0-2
排除标准
- •1. Previous or concomitant use of biphosphonates
- •2. Prior chemotherapy or radiotherapy within 4 weeks prior to treatment start
- •3. Uncontrolled hypercalcemia
- •4. Brain metastases
- •5. Previous or concomitant malignancies
- •6. Uncontrolled systemic disease of infection
研究者
相似试验
已完成
不适用
Randomized phase II/III study of Risedronate in combination with Docetaxel versus Docetaxel alone in patients with hormone refractory prostate cancer.NL-OMON22637ot applicable480
已完成
不适用
Clinical outcome of risedronate therapy for patients with Paget's disease of bonePaget's disease of boneJPRN-UMIN000019338agoya University Hospital15
已完成
4 期
Efficacy of monthly sodium risedronate for the treatment of corticosteroid induced osteoporosis in patients with rheumatoid arthritis (multicenter, double-blind, randomized, placebo-controlled, parallel-group study )osteoporosis, rheumatoid arthritisJPRN-UMIN000015794Division of rheumatology, endcrinology and nephrology, Hokkaido University Graduate School of Medicine165
已完成
2 期
A randomized phase II study of efficacy of risendronate for the prevention of letrozole-induced bone mineral loss in post-menopausal breast cancer patientsbreast cancerJPRN-UMIN000005568Hiroshima University120
已完成
不适用
Effects of risedronate on the progression of aortic valv stenosis in osteoporosis patientsAortic valve stenosis with osteoporosisJPRN-UMIN000003226Juntendo University School of Medcine, The department of Cardiology180